Novo Nordisk, the pharmaceutical company behind Ozempic, has launched a national campaign promoting its injectable ...
Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are ...
Investors interested in the pharmaceutical industry are currently excited about the anti-obesity market. Weight-loss ...
FAT jabs could be the cancer hope of the future after early studies found they reduce the risk of tumours. The world’s top ...
While Novo Nordisk charges $1,349 a month for Wegovy in the U.S., the drug costs just $140 a month in Germany and $92 a month in the U.K. Novo Nordisk has blamed middlemen in the U.S. healthcare ...
A recent US study has found that weight loss medications like Wegovy and Ozempic may increase the risk of abdominal paralysis ...
As chronic kidney disease rises nationwide, a new study partially conducted in Orlando suggests weight loss drugs like Ozempic and Wegovy could be part of the solution.
Have a question for Alyssa Northrop or our other editors? Ask here for a chance to be featured in a story. Thank you for submitting your question. Keep reading Forbes Advisor for the chance to see ...
Several promising drugs in phase 2 testing and beyond seek to offer patients a more convenient alternative to already popular ...
Structure Therapeutics’ GLP-1 receptor agonist GSBR-1290 achieved mean weight loss of 6.2% in overweight or obese patients.
Now that’s more like it. After investors frowned on Structure Therapeutics’ oral GLP-1 data in December 2023, the biotech is ...